Invent Medic Sweden AB today presents the Annual Report for 2019 and the Proposal for Decision for the upcoming Annual General Meeting on May 5, 2020 in Lund.
CEO Karin Bryder summarises the year
2019 was characterised by a commercial breakthrough for Invent Medic’s first product Efemia bladder support. During
the year, we were able to successfully establish the product and present upcoming launches in six European countries,
including the UK and Germany, and the sales numbers for Efemia began to gain momentum in Q4. Additionally, the
first Efemia order was received from a Swedish healthcare region. After the end of the year, a fully subscribed share
issue of 29.8 MSEK (before issuing costs) was conducted. This will allow us to continue our expansion and offer Efemia
in additional European markets and the United States within three years. We have been affected by the Covid-19
pandemic, with marketing activities being postponed or cancelled, but our sales in Q1 2020 remained stable and we
expect the total sales figure to be in line with Q4 2019. Additionally, we do not expect our ongoing preparations for the
launch in the United States to be affected by this situation.